Celtrix receives two additional U.S. patents.SANTA CLARA, Calif.--(BW HealthWire)--May 22, 1997--Celtrix Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CTRX CTRX Contractions (labor & delivery) ) announced today that it has received two additional patents from the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property , further protecting its proprietary technology relating to the production and use of SomatoKine(R), the company's novel IGF-BP3 complex. SomatoKine is currently undergoing early-stage Phase II human clinical testing. U.S. Patent No. 5,629,172, entitled "Expression of Fusion Polypeptides Transported Out of the Cytoplasm cytoplasm: see protoplasm. cytoplasm Portion of a eukaryotic cell outside the nucleus. The cytoplasm contains all the organelles (see eukaryote). Without Leader Sequences," relates to recombinant protein production using fusion protein technology. The new patent, which is related to U.S. Patent No. 5,563,046 issued to Celtrix last year, claims compositions and methods involving fusion proteins which use variants of the bacterial proteins DsbA and DsbC as fusion partners. The claimed compositions and methods are generally applicable to the production of recombinant proteins and may be useful in the manufacture of SomatoKine. U.S. Patent No. 5,624,805, entitled "Uses for Antibodies Which Bind to Human Somatomedin somatomedin /so·ma·to·me·din/ (so?mah-to-me´din) any of a group of peptides found in plasma, complexed with binding proteins; they stimulate cellular growth and replication as second messengers in the somatotropic actions of growth Carrier Protein Subunits," was issued with claims relating to the use of antibodies to an insulin-like growth factor insulin-like growth factor one of the twenty or so substances, additional to the classic bone-regulating hormones, which exert an effect on bone cell metabolism. See also somatomedin C. (IGF (Internet Governance Forum) An international organization of governments and U.N. agencies that was founded to discuss Internet issues such as security and spam. It was created at the United Nations Summit in 2005 after the U.S. ) binding protein in methods for determining levels of free (unbound unbound said of electrolytes, e.g. iron and calcium, and other substances which are circulating in the bloodstream and are not bound to plasma proteins so that they are available immediately for metabolic processes. See also calcium, iron. ) IGF. Celtrix is a biopharmaceutical company developing novel therapeutics for the treatment of seriously debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction , degenerative conditions primarily associated with severe trauma, chronic diseases or aging. The company's focus is on SomatoKine, a novel IGF-BP3 complex, for use in regenerating lost muscle, bone and other tissues essential for the patient's health and quality of life. Initial product development programs target acute traumatic injury, such as hip fracture surgery in the elderly, and severe burns. Other potential indications include severe osteoporosis and protein wasting diseases associated with cancer, AIDS and other life-threatening conditions. Through strategic alliances with Celtrix, The Green Cross Corporation is developing SomatoKine for the treatment of osteoporosis in Japan, and Genzyme Corporation is developing TGF-beta-2 as part of a comprehensive approach to tissue repair and the treatment of systemic disease. This news release contains certain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Actual results may differ materially from the statements made, as a result of various factors, including risks associated with unforeseen interference proceedings related to these new patents, ability of third parties to engineer or develop processes or products around these patent claims, future company research, clinical study results, the regulatory approval process, competitive products and other factors which are listed from time to time in Celtrix's Securities and Exchange Commission (SEC) filings. These forward-looking statements represent Celtrix's judgment as of the date of this news release. CONTACT: Celtrix Pharmaceuticals, Inc. David M. Rosen Ph.D., 408/988-2500 (VP - Research and Development) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion